Gossamer Bio, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GOSS research report →
Range $32 – $32
Price Chart
About the company
Gossamer Bio, Inc. , a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.
- CEO
- Faheem Hasnain
- IPO
- 2019
- Employees
- 162
- HQ
- San Diego, CA, US
Get TickerSpark's AI analysis on GOSS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $65.57M
- P/E
- -0.31
- Fwd P/E
- 10.81
- PEG
- -0.01
- P/S
- 0.88
- P/B
- -0.60
- EV/EBITDA
- -0.28
- Div Yield
- 0.00%
- Gross Margin
- 99.70%
- Op Margin
- -139.99%
- Net Margin
- -159.49%
- ROE
- 99.85%
- ROIC
- -4305.64%
Latest fiscal year · YoY change
- Revenue
- $48.47M-57.7%
- Gross Profit
- $47.47M-58.6%
- Op Income
- $-163,253,000
- Net Income
- $-170,370,000-201.4%
- EPS
- $-59.64-198.3%
- OCF Growth
- -4838.5%
- FCF Growth
- -4840.7%
- 52W High
- $309.60
- 52W Low
- $8.29
- 50D MA
- $10.40
- 200D MA
- $27.50
- Beta
- 2.00
- RSI (14)
- 51
- Avg Volume
- 266.06K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Gossamer Bio said PROSERA’s mixed primary readout still supports a seralutinib NDA path, backed by new CT imaging evidence, FDA engagement, and a major balance-sheet reset.· May 18, 2026
- PROSERA’s primary endpoint met the 0.05 threshold but missed the prespecified 0.025 alpha; management still sees a clinically meaningful effect.
- The prespecified CT FRI substudy showed multi-compartment reverse remodeling signals in arteries, veins, and fibrosis-like parenchyma, with clinical correlations.
- FDA moved the company from a Type C to a Type B pre-NDA meeting; the NDA target remains September 2026, with potential approval in Q3 2027.
- Gossamer cut about half the workforce and reduced spending as PROSERA winds down.
- The company exchanged convertible notes, reducing debt from $200 million to $72 million on a fully subscribed basis and extending maturity from 2027 to 2030.
As of March 31, 2026, Gossamer reported $99 million of cash and cash equivalents plus marketable securities. Management said PROSERA showed a placebo-adjusted improvement of 13.3 meters in 6-minute walk distance at week 24, with seralutinib patients improving 28.2 meters from baseline versus 13.5 meters on placebo and a p-value of 0.032; the result did not meet the prespecified 0.025 alpha threshold. In the CT FRI substudy, 162 patients enrolled and 125 had evaluable paired scans at week 24. The company said all 4 key secondary endpoints favored seralutinib, and the prespecified risk-enriched subgroup showed a stronger effect. On capital structure, a full exchange would reduce convertible debt from $200 million to $72 million and extend maturity from 2027 to 2030. Management expects cash runway into the first quarter of 2027, with operating expenses coming down and go-forward quarterly burn lower after the workforce reduction and PROSERA wind-down. The company targets NDA submission in September 2026, subject to the pre-NDA meeting outcome, and said potential approval could follow in the third quarter of 2027.
Faheem Hasnain framed the quarter as a step forward despite the missed prespecified alpha, arguing that the totality of PROSERA, TORREY, and the new CT FRI data strengthens conviction in seralutinib. He emphasized the company acted quickly on capital stewardship, including a reduction in force, cost cuts, and noteholder negotiations, to preserve runway and execution focus. His tone was confident and urgent, repeatedly stressing that the company owes it to PAH patients to pursue approval.
Bryan Giraudo said Gossamer ended the quarter with $99 million in cash and marketable securities and expects runway into Q1 2027. He noted operating expenses should decline as PROSERA winds down, with one-time charges in Q1 and lower ongoing burn after the reduction in force and broader cost containment. On the balance sheet, he said the convertible exchange would lower outstanding debt by $128 million on a fully subscribed basis, leaving $72 million outstanding and pushing maturity to 2030; the new notes carry a 7.5% cash interest rate and a first-priority lien on substantially all assets.
Analysts focused on how the CT FRI data would support the pre-NDA meeting, the NDA label, and commercialization. Management said the imaging data were not in the pre-NDA briefing book because they came too late, but they will be highlighted at the meeting and included in the NDA, potentially in the pharmacodynamic section of the label. Questions also centered on patient selection and whether seralutinib might be used earlier or across the PAH spectrum; management said the strongest effect appears in intermediate-to-high-risk patients, but they also see potential earlier use because of the safety profile and the reverse-remodeling story.
Management believes the data package now includes not just a clinical signal but mechanistic evidence of multi-compartment structural remodeling, which they think could be differentiated in PAH. The FDA has granted an in-person Type B pre-NDA meeting, the NDA timeline remains on track for September 2026, and management sounded more confident after engaging noteholders and resetting the capital structure.
The primary PROSERA endpoint missed the stricter prespecified alpha threshold, so the path forward still depends on FDA acceptance of a one-study-plus-confirmatory-evidence framework. The CT FRI work is described as prespecified exploratory and nominal/unadjusted for multiplicity, and management acknowledged the technology is not standard clinical practice. The company also remains dependent on a September NDA filing and a 2027 approval timeline while burning down cash, even after the debt exchange and cost cuts.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 26.3%
- Shares Outstanding
- 6.12M
- Float Shares
- 1.61M
of shares held by institutions
177 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| D. E. Shaw & Co., Inc. | 40.96M | ▲ 40.57M |
| 683 Capital Management, LLC | 39.20M | ▲ 34.20M |
| Aqr Capital Management LLC | 15.63M | ▲ 5.50M |
| Gsa Capital Partners Llp | 14.99M | ▲ 11.73M |
| Vanguard Group Inc | 12.87M | ▲ 863.44K |
| Arch Venture Management, LLC | 8.06M | 0 |
| Octagon Capital Advisors LP | 7.75M | 0 |
| Two Sigma Investments, LP | 7.43M | ▲ 2.65M |
| Samsara Biocapital, LLC | 7.22M | 0 |
| Corient Private Wealth LP | 5.63M | ▲ 1.65M |
| Hhlr Advisors, Ltd. | 4.97M | 0 |
| Two Sigma Advisers, LP | 2.60M | ▲ 726.80K |
Held by 66 ETFs
Biggest fund positions in GOSS by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 23, 26 | Milligan Sandra | other | 10,000 |
| Sep 23, 26 | Daniel Thomas O | other | 10,000 |
| Sep 23, 26 | Ciongoli Gregory Austin | other | 30,000 |
| Sep 23, 26 | Drynan Skye | other | 10,000 |
| Sep 23, 26 | Quisel John D | other | 10,000 |
| Sep 23, 26 | Cox Russell J. | other | 10,000 |
| Sep 23, 26 | Nathan Steven D | other | 10,000 |
| Aug 24, 26 | Ciongoli Gregory Austin | other | 0 |
| Aug 24, 26 | Christian Waage | other | 2,900,026 |
| Aug 24, 26 | Peterson Caryn | other | 5,800,051 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our GOSS coverage
Recent articles, reports, and earnings notes.
No research on GOSS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate GOSS report →Does Gossamer Bio (GOSS) Have the Potential to Rally 659.56% as Wall Street Analysts Expect?
zacks.com · Nov 17
Gossamer Bio Analysts Slash Their Forecasts Following Q3 Results
benzinga.com · Nov 11
Gossamer Bio Announces Third Quarter 2026 Financial Results and Provides Business Update
businesswire.com · Nov 10
Corient Private Wealth LP Purchases 1,647,315 Shares of Gossamer Bio, Inc. $GOSS
defenseworld.net · Sep 28
Gossamer Bio Submits New Drug Application to U.S. FDA for Seralutinib for the Treatment of Pulmonary Arterial Hypertension
businesswire.com · Sep 23
Hsbc Holdings PLC Increases Stock Position in Gossamer Bio, Inc. $GOSS
defenseworld.net · Sep 17
Gossamer Bio Appoints Greg Ciongoli to Board of Directors
businesswire.com · Sep 16
Gossamer Bio Announces Effectiveness of 1-for-80 Reverse Stock Split
gurufocus.com · Sep 11
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.